Mesalamine: all 93 studies that test it

Page 1 of 1. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.

• ASAPP Study - Topical 5-ASA as Prophylaxis for Pouchitis in Ulcerative Colitis Patients After Pelvic Pouch SurgeryNot yet recruitingNCT07773948Phase 4
• ND-12 Combined With H-6 for Adult Chronic Inflammatory DiarrheaRecruitingNCT07767370Early Phase 1
• TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITISNot yet recruitingNCT06625450Phase 4
• Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.Not yet recruitingNCT06176560Phase 3
• Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)RecruitingNCT05663775Phase 2
• Mesalamine for Colorectal Cancer Prevention Program in Lynch SyndromeRecruitingNCT04920149Phase 2
• Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative ColitisRecruitingNCT04133194Phase 4
• Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)CompletedNCT02522780Phase 3Results posted
• Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)CompletedNCT02522767Phase 3Results posted
• Taste Assessment Study of SHP429 in Healthy Adult SubjectsCompletedNCT02125292Phase 1Results posted
• Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative ColitisCompletedNCT02093663Phase 3Results posted
• Correlation of Mesalamine Pharmacokinetics With Local AvailabilityCompletedNCT01999400Not applicableResults posted
• Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/MesalamineCompletedNCT01469637Phase 1Results posted
• Amoxicillin Drug Interaction Study With MMX® Mesalazine/MesalamineCompletedNCT01442688Phase 1Results posted
• Metronidazole Drug Interaction Study With MMX® Mesalazine/MesalamineCompletedNCT01418365Phase 1Results posted
• The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot StudyCompletedNCT01412372Phase 3Results posted
• Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/MesalamineCompletedNCT01402947Phase 1Results posted
• Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)CompletedNCT01327300Phase 2Results posted
• Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative ColitisCompletedNCT01124149Phase 4Results posted
• Mesalamine to Reduce T Cell Activation in HIV InfectionCompletedNCT01090102Phase 4Results posted
• Targeting Oxidative Stress in Chronic Beryllium DiseaseCompletedNCT01088243Phase 1/2Results posted
• Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative ColitisCompletedNCT01059344Phase 3Results posted
• Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative ProctitisTerminatedNCT01016262Phase 3Results posted
• Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative ColitisTerminatedNCT01004185Phase 3Results posted
• A Study With Pentasa in Patients With Active Crohn's DiseaseTerminatedNCT00862121Phase 3Results posted
• Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative ColitisCompletedNCT00713310Phase 3Results posted
• Dose Escalation and Remission (DEAR)CompletedNCT00652145Phase 4Results posted
• Canadian Active & Maintenance Modified Pentasa StudyCompletedNCT00603733Phase 3Results posted
• Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)CompletedNCT00577473Phase 3Results posted
• Asacol Acute Diverticulitis(DIVA)StudyCompletedNCT00554099Phase 2Results posted
• Prevention of Recurrence of DiverticulitisCompletedNCT00545103Phase 3Results posted
• Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)CompletedNCT00446849Phase 4Results posted
• Safety and Compliance of Taking Mesalamine Once a Day in Pediatric PatientsTerminatedNCT00349388Not applicableResults posted
• Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative ColitisCompletedNCT00151892Phase 3Results posted
• Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative ColitisCompletedNCT00073021Phase 3Results posted
• ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASACompletedNCT05992142Phase 4
• Mesalazine Oral Suspension in Active Eosinophilic EsophagitisCompletedNCT05488405Phase 2
• A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative ColitisWithdrawnNCT05316220Phase 3
• Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative ColitisCompletedNCT05205603Phase 4
• The Safety and Efficacy of TET Enema in the Treatment of UCStatus unknownNCT03917095Not applicable
• Role of Intestinal Protozoa and Helminths in the Course of Ulcerative ColitisActive, not recruitingNCT03441893Phase 1/2
• Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female SubjectsCompletedNCT03327558Phase 1
• Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative ColitisStatus unknownNCT03110198Phase 4
• Mesalamine for Colorectal Cancer Prevention Program in Lynch SyndromeTerminatedNCT03070574Phase 2
• The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral UlcerWithdrawnNCT02769494Phase 3
• Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative ColitisCompletedNCT02537210Not applicable
• TP0502-B-Pharmaco-Scintigraphic-StudyCompletedNCT02306798Phase 1
• TP0502-Pharmaco-Scintigraphic-Study and AmendmentCompletedNCT02306785Phase 1
• TP0501 - Pharmaco-Scintigraphic-StudyCompletedNCT02306772Phase 1
• Effects of Mesalamine and Amitriptyline on Irritable Bowel SyndromeWithdrawnNCT02190526Phase 4
• Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.CompletedNCT02077777Phase 2
• Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative ColitisCompletedNCT01941589Phase 4
• Mesalazine Effects in Sporadic Colorectal Adenoma PatientsCompletedNCT01894685Phase 2
• Mesalamine in Environmental EnteropathyCompletedNCT01841099Phase 1/2
• Clinical Management of Childhood Intestinal Lymphoid Nodular HyperplasiaStatus unknownNCT01789294Phase 4
• Mesalazine Treatment in IBS (The MIBS Study)CompletedNCT01699438Phase 2
• Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled StudyCompletedNCT01627262Phase 2
• Mesalazine and/or Lactobacillus Casei in the Diverticular Disease of the ColonCompletedNCT01534754Phase 4
• Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)CompletedNCT01316718Phase 4
• Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission PhaseCompletedNCT01257399Phase 3
• Comparative Efficacy and Safety Study in Patients With Active Ulcerative ColitisCompletedNCT01257386Phase 3
• Budesonide Versus Mesalazine Versus Placebo in Lymphocytic ColitisCompletedNCT01209208Phase 3
• Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative ColitisCompletedNCT01201122Phase 4
• Clinical Trial With Mesalamine 1g SuppositoriesTerminatedNCT01172444Phase 3
• Evaluation of Efficacy of Mesalamine in the Long-term Prevention of Diverticulitis FlaresCompletedNCT01120340Phase 3
• A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative ColitisCompletedNCT01045018Phase 3
• Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of DiverticulitisTerminatedNCT01038739Phase 3
• Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative ColitisCompletedNCT01020708Phase 1
• Trial of Mesalamine for the Treatment of Active Microscopic ColitisCompletedNCT00952952Phase 2/3
• Bioavailability Study of Two Mesalamine 4 gm/60 ml Rectal Enema FormulationsCompletedNCT00802451Not applicable
• A Randomized Controlled Pilot Trial of Mesalazine in Patients With Irritable Bowel SyndromeCompletedNCT00774007Phase 2/3
• Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy VolunteersCompletedNCT00751699Phase 1
• Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)CompletedNCT00746447Phase 3
• Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.CompletedNCT00737789Phase 3
• The Colitis Once Daily Asacol StudyCompletedNCT00708656Phase 3
• Mesalazine Granules vs. Placebo for the Prevention of Recurrence of DiverticulitisTerminatedNCT00695643Phase 3
• Mesalazine Therapy in Patients With Irritable Bowel SyndromeCompletedNCT00626288Phase 3
• PK Study of Encapsulated Mesalamine Granules in Healthy VolunteersCompletedNCT00622375Phase 1
• Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative ColitisCompletedNCT00548574Phase 3
• Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476CompletedNCT00545389Phase 2
• Medical Treatment of Colitis in Patients With Hermansky-Pudlak SyndromeWithdrawnNCT00514982Phase 2
• Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous ColitisCompletedNCT00450086Phase 3
• OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative ColitisCompletedNCT00449722Phase 3
• A Double Blind Study for the Treatment of Acute Ulcerative ColitisCompletedNCT00350415Phase 3
• Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative ColitisCompletedNCT00343850Phase 3
• A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.TerminatedNCT00254618Phase 1
• The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active "Drug: Crohn's Disease"TerminatedNCT00245505Phase 3
• Pentasa Once Daily in Ulcerative Colitis for Maintenance of RemissionCompletedNCT00209300Phase 3
• Asacol Dosing Study for Active Ulcerative ColitisCompletedNCT00194818Phase 4
• The Influence of 5-Aminosalicylates on Thiopurine Metabolite LevelsCompletedNCT00167882Phase 4
• Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis.CompletedNCT00151944Phase 3
• CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) RemissionCompletedNCT00092508Phase 3
• Effect of an Anti-Inflammatory Drug on Gut Mucosa in HIV Infected PatientsCompletedNCT00069498Phase 1

← Mesalamine overview